A study of a GLP-1 medicine, orforglipron, in people with endometrioid endometrial adenocarcinoma.
Recruiting now. Registry record last updated June 8, 2026.
- Who can join
- Adults 18+, women only, have endometrioid endometrial adenocarcinoma, BMI 30+.
- What you take
- orforglipron, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 3.6 years; your own time in it is usually shorter.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Endometrioid Endometrial Adenocarcinoma.
Full scientific study title: A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device i.
Who can join
Adults 18+, women only, have endometrioid endometrial adenocarcinoma, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Adults ≥ 18 years old
- A pathological diagnosis with in the past 4 months consistent with grade 1 endometrioid endometrial adenocarcinoma or EIN
- For subjects with a diagnosis of endometrial intraepithelial neoplasia/grade 1 endometrioid endometrial adenocarcinoma prior to enrollment in the study, and with a diagnosis made outside this institution, the diagnostic material originating from outside the study site will undergo in-house pathology review before enrollment acceptance.
- ECOG Performance Status of 0 to 3
- For those with endometrial cancer, no extrauterine involvement or myometrial invasion by MRI (preferred) or transvaginal ultrasound
Key exclusion criteria
- Subjects with grade 2 or 3 endometroid or any non-endometrioid histology (i.e., clear cell, carcinoma, serous)
- Clinical suspicion of metastatic disease as assessed by the treating physician or confirmed metastatic disease based on imaging
- Subjects with abnormal cervical cytology
- Subjects who are diagnosed with thyroid cancer, pancreatitis, or multiple endocrine neoplasia syndrome type 2
- Subjects who are confirmed to be pregnant or breastfeeding
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Florida1 site
- University of FloridaGainesville, Florida
Timeline
Started enrolling: April 7, 2026. Expected completion: November 2029. Last updated on ClinicalTrials.gov: June 8, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
